Epidemiology of end-stage kidney disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
End-stage kidney disease (ESKD) is a common and morbid disease that affects patients’ quality and length of life, representing a large portion of health care expenditure in the United States. These patients commonly have associated diabetes and cardiovascular disease, with high rates of cardiovascular-related death. Management of ESKD requires renal replacement therapy via dialysis or transplantation. While transplantation provides the greatest improvement in survival and quality of life, the vast majority of patients are treated initially with hemodialysis. However, outcomes differ significantly among patient populations. Barriers in access to care have particularly affected at-risk populations, such as Black and Hispanic patients. These patients receive less pre-ESKD nephrology care, are less likely to initiate dialysis with a fistula, and wait longer for transplants—even in pediatric populations. Priorities for ESKD care moving into the future include increasing access to nephrology care in underprivileged populations, providing patient-centered care based on each patient’s “life plan,” and focusing on team-based approaches to ESKD care. This review explores ESKD from the perspective of epidemiology, costs, vascular access, patient-reported outcomes, racial disparities, and the impact of the COVID-19 crisis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017) · JAMA · doi:10.1001/jama.2017.7156 · Cited by 2,302 · cited 1×
“The use of PROs can also improve outcomes; chemotherapy patients experienced increased survival when periodic assessment of PROs was implemented, alerting physicians when alarming symptoms were registered [50].”
BackgroundStandardizing Patient Outcomes Measurement
Porter, M. E., Larsson, S., & Lee, T. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1511701 · Cited by 626 · cited 1×
“their health care and enhance patients’ ability to participate in the vascular access decisionmaking process [49].”
Background. Prediction, progression and outcomes of chronic kidney disease in older adults.
Anderson, S., Halter, J. B., Hazzard, W. R., Himmelfarb, J., Horne, F. M., Kaysen, G. A., Kusek, J. W., Nayfield, S. G., Schmader, K., Tian, Y., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080860 · Cited by 218 · cited 1×
“The relatively low rate of progression is due in part to high rates of cardiovascular-related death before onset of ESKD [7].”
BackgroundXue, J. L., Eggers, P. W., Agodoa, L. Y., Foley, R. N., & Collins, A. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050524 · Cited by 117 · cited 1×
“CKD patients with proteinuria, hypertension, and diabetes, as well as Black and Hispanic CKD patients, all have a 2- to 3fold greater risk of progression to ESKD than patients without these risk factors [9].”
Background
Cited by
Artificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Zhu, Y., Zhang, Y., Yang, M., Tang, N., Liu, L., Wu, J., & Yang, Y. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458263 · Cited by 14
Metadata
- Authors
- Gupta, R., Woo, K., & Yi, J. A.
- Venue
- Seminars in Vascular Surgery
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 34
- Issue
- 1
- Pages
- 71-78
- ISSN
- 0895-7967 (ISSN-L)
- OpenAlex
- W3128070618
- Cited by
- 186
- References
- 4
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology of end-stage kidney disease. https://app.cochat.ai/papers/10.1053/j.semvascsurg.2021.02.010
- The paper
- Gupta, R., Woo, K., & Yi, J. A. (2021). Epidemiology of end-stage kidney disease. Seminars in Vascular Surgery. https://doi.org/10.1053/j.semvascsurg.2021.02.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.